Ischemic heart disease is a leading worldwide cause of death. The Seattle Post Myocardial Infarction Model (SPIM) was developed to predict survival 6 months to 2 years after an acute myocardial infarction with evidence of left ventricular dysfunction.
Methods and Results:
A total of 6632 subjects from the EPHESUS trial were used to derive the predictive model, while 5477 subjects from the OPTIMAAL trial were used to validate the model. Cox proportional hazards modeling was used to develop a multivariate risk score predictive of all-cause mortality. The SPIM risk score integrated lab and vital parameters, Killip class, reperfusion or revascularization, the number of cardiac evidence-based medicines (aspirin, statin, β blocker, ACEI/ARB, aldosterone blocker), and the number of cardiac risk factors. The model was predictive of all-cause mortality after myocardial infarction, with an AUC of 0.75 at 6 months and 0.75 at 2 years in the derivation cohort and 0.77 and 0.78 for the same time points in the validation cohort. Model predicted versus Kaplan-Meier observed survival was excellent in the derivation cohort. It remained so in the validation cohort—84.9% versus 85.0% at 2 years. The 10% of subjects with the highest predicted risk had approximately 25 times higher mortality at 2 years than the 10% of subjects with the lowest predicted risk.
Conclusion:
The SPIM score was a powerful predictor of outcomes after myocardial infarction with left ventricular dysfunction. Its highly accurate predictions should improve patient and physician understanding of survival and may prove a useful tool in post-infarct risk stratification.
KrumholzHMWangYChenJ. Reduction in acute myocardial infarction mortality in the United States: Risk-standardized mortality rates from 1995–2006. JAMA2009; 302: 767–773.
2.
YehRWSidneySChandraM. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med2010; 362: 2155–2165.
3.
PuymiratESimonTStegPG. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA2012; 308: 998–1006.
4.
JernbergTJohansonPHeldC. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA2011; 305: 1677–1684.
5.
FordESAjaniUACroftJB. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med2007; 356: 2388–2398.
6.
GrangerCBGoldbergRJDabbousO. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med2003; 163: 2345–2353.
7.
AntmanEMCohenMBerninkPJ. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA2000; 284: 835–842.
8.
MorrowDAAntmanEMCharlesworthA. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation2000; 102: 2031–2037.
9.
BoersmaEPieperKSSteyerbergEW. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation2000; 101: 2557–2567.
10.
McManusDDGoreJYarzebskiJ. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med2011; 124: 40–47.
11.
RogerVLGoASLloyd-JonesDM. Heart disease and stroke statistics – 2012 update: A report From the American Heart Association. Circulation2012; 125: e2–e220.
12.
DicksteinKGleimGWSnapinnS. The impact of morbid events on survival following hospitalization for complicated myocardial infarction. Eur J Heart Fail2006; 8: 74–80.
13.
JacobsDRJrKroenkeCCrowR. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: The Minnesota Heart Survey. Circulation1999; 100: 599–607.
14.
BrilakisESWrightRSKopeckySL. Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction. Am Heart J2003; 146: 811–818.
15.
TruongQACannonCPZakaiNA. Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trial. Am Heart J2009; 157: 673–679.
16.
GargSSarnoGGarcia-GarciaHM. A new tool for the risk stratification of patients with complex coronary artery disease: The Clinical SYNTAX Score. Circ Cardiovasc Interv2010; 3: 317–326.
17.
EagleKALimMJDabbousOH. A validated prediction model for all forms of acute coronary syndrome: Estimating the risk of 6-month postdischarge death in an international registry. JAMA2004; 291: 2727–2733.
18.
PittBRemmeWZannadF. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med2003; 348: 1309–1321.
19.
PittBWilliamsGRemmeW. The EPHESUS trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther2001; 15: 79–87.
20.
DicksteinKKjekshusJ.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet2002; 360: 752–760.
21.
DicksteinKKjekshusJ.Comparison of baseline data, initial course, and management: Losartan versus captopril following acute myocardial infarction (The OPTIMAAL Trial). OPTIMAAL Trial Steering Committee and Investigators. Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan. Am J Cardiol2001; 87: 766–771, A7.
22.
HanleyJAMcNeilBJ.The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology1982; 143: 29–36.
23.
LemeshowSHosmerDWJr.A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol1982; 115: 92–106.
24.
AndersonKMWilsonPWOdellPM. An updated coronary risk profile. A statement for health professionals. Circulation1991; 83: 356–362.
25.
WilsonPWD’AgostinoRBLevyD. Prediction of coronary heart disease using risk factor categories. Circulation1998; 97: 1837–1847.
26.
BhattDLEagleKAOhmanEM. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA2010; 304: 1350–1357.
27.
DonahoeSMStewartGCMcCabeCH. Diabetes and mortality following acute coronary syndromes. JAMA2007; 298: 765–775.
28.
PepineCJKoweyPRKupferS. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol2006; 47: 547–551.
29.
LevyWCMozaffarianDLinkerDT. The Seattle heart failure model: Prediction of survival in heart failure. Circulation2006; 113: 1424–1433.
30.
LevyDKenchaiahSLarsonMG. Long-term trends in the incidence of and survival with heart failure. N Engl J Med2002; 347: 1397–1402.
31.
GiuglianoRPLlevadotJWilcoxRG. Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J2001; 22: 1702–1715.
32.
AlbertsMJBhattDLMasJL. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J2009; 30: 2318–2326.
33.
StegPGBhattDLWilsonPW. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA2007; 297: 1197–1206.
34.
CohenMGPacchianaCMCorbalanR. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Am Heart J2001; 141: 391–401.
35.
GibsonCMPintoDSMurphySA. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol2003; 42: 1535–1543.
36.
KumlerTGislasonGHKoberL. Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years. BMC Cardiovasc Disord2011; 11: 37.
37.
GiraldezRRSabatineMSMorrowDA. Baseline hemoglobin concentration and creatinine clearance composite laboratory index improves risk stratification in ST-elevation myocardial infarction. Am Heart J2009; 157: 517–524.
38.
AnkerSDVoorsAOkonkoD. Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: Data from the OPTIMAAL trial. Eur Heart J2009; 30: 1331–1339.
39.
KleinLO'ConnorCMLeimbergerJD. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation2005; 111: 2454–2460.
40.
BangaloreSMesserliFHOuFS. The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: Results from 135 164 patients in the CRUSADE quality improvement initiative. Eur Heart J2010; 31: 552–560.
41.
AntoniMLBodenHDelgadoV. Relationship between discharge heart rate and mortality in patients after acute myocardial infarction treated with primary percutaneous coronary intervention. Eur Heart J2012; 33: 96–102.
42.
WiviottSDMorrowDAFrederickPD. Application of the thrombolysis in myocardial infarction risk index in non-ST-segment elevation myocardial infarction: Evaluation of patients in the National Registry of Myocardial Infarction. J Am Coll Cardiol2006; 47: 1553–1558.
43.
YanATYanRTCantorWJ. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). Eur Heart J2011; 32: 1994–2002.
44.
Van DomburgRTSonnenscheinKNieuwlaatR. Sustained benefit 20 years after reperfusion therapy in acute myocardial infarction. J Am Coll Cardiol2005; 46: 15–20.
45.
WrightRSAndersonJLAdamsCD. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol2011; 57: e215–367.
46.
BagnallAJYanATYanRT. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: Exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes2010; 3: 530–537.
47.
YanATYanRTHuynhT. Understanding physicians’ risk stratification of acute coronary syndromes: Insights from the Canadian ACS 2 Registry. Arch Intern Med2009; 169: 372–338.
